Chondroblastoma of the temporal bone

A rare case of chondroblastoma arising from the temporal bone that occurred in a 60-year-old woman is reported. The tumor appeared well demarcated and osteolytic on the radiographs. CT scan clearly depicted marginal and central calcification in the tumor. MR imaging demonstrated two components in the tumor: a solid component with predominantly low signal intensities on both T1- and T2-weighted sequences, and a multilocular cystic component with T1- and T2-elongation and fluid-fluid levels on the T2-weighted images. Postcontrast MR imaging revealed marked enhancement in the solid component and the septa of the cystic component.     

Characteristics of myocardial ischemia in patients with chronic renal failure and its relation to cardiac sympathetic activity

In order to clarify the characteristics of myocardial ischemia in patients with chronic renal failure (CRF), we performed exercise stress myocardial perfusion imaging with 99mTc-MIBI in 36 patients with CRF. In 18 patients myocardial imaging with 123I-MIBG (MIBG) and 201Tl was performed at rest to evaluate myocardial sympathetic activities: cardiac uptake of MIBG normalized by myocardial perfusion (Uptake Ratio, UR) and myocardial washout rate of MIBG (WO). Exercise-induced perfusion abnormality was observed in 25 patients, and coronary angiography was performed in 19 of them. Among 25 diseased coronary arteries, 18 developed perfusion abnormalities in the myocardial segments which were supplied by each coronary artery. However in 5 patients without coronary artery stenosis and 2 patients with left anterior descending coronary artery disease, transient perfusion abnormalities were observed in the inferior segments. In 6 of them, MIBG imaging was obtained (Group A). MIBG imaging was also performed in 5 patients with transient inferior perfusion abnormality with coronary artery stenosis which supplied the inferior wall (Group B), and 7 patients without perfusion abnormality (Group C). In the patients of Group B, inferior UR was significantly lower than in Group C (0.58 +/- 0.07 vs. 0.68 +/- 0.08, p = 0.0485) and inferior WO was more accelerated than in Group C (18.6 +/- 7.7 vs. 12.1 +/- 6.0%, NS). However anterior UR and Wo levels were identical with those in Group C. In Group A, inferior UR (0.43 +/- 0.05) was significantly lower than in Group B and C, and WO in Group A (27.2 +/- 8.3%) was accelerated significantly compared to that in Group C. Besides in Group A, anterior UR was significantly smaller and WO was greater than in Group B and C. These findings suggested that in some patients with CRF, myocardial ischemia could arise without coronary artery stenosis, and this phenomenon might be related to abnormalities of cardiac sympathetic activity.     

Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study

Journal of Gastroenterology - ABC classification has been used to assess the risk for gastric cancer. The current problem of ABC classification is that Group A contains individuals with current and...     

Potentiality of immunotherapy against hepatocellular carcinoma

Hepatocellular carcinoma(HCC),the predominant form of primary liver cancer,is the fifth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence,treatment options remain limited for advanced HCC,and as a result prognosis continues to be poor. Current therapeutic options,surgery,chemotherapy and radiotherapy,have only modest efficacy. New treatment modalities to prolong survival and to minimize the risk of adverse response are desperately needed for patients with advanced HCC. Tumor immunotherapy is a promising,novel treatment strategy that may lead to improvements in both treatment-associated toxicity and outcome. The strategies have developed in part through genomic studies that have yielded candidate target molecules and in part through basic biology studies that have defined the pathways and cell types regulating immune response. Here,we summarize the various types of HCC immunotherapy and argue that the newfound field of HCC immunotherapy might provide critical advantages in the effort to improve prognosis of patients with advanced HCC. Already several immunotherapies,such as tumor-associated antigen therapy,immune checkpoint inhibitors and cell transfer immunotherapy,have demonstrated safety and feasibility in HCC patients. Unfortunately,immunotherapy currently has low efficacy in advanced stage HCC patients; overcoming this chal lenge will place immunotherapy at the forefront of HCC treatment,possibly in the near future.